De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioCryst Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO BioCryst Pharmaceuticals' is Jon Stonehouse, benoemd in Jan2007, heeft een ambtstermijn van 17.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.78M, bestaande uit 13.9% salaris en 86.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.43% van de aandelen van het bedrijf, ter waarde $ 6.71M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 5.2 jaar.
Belangrijke informatie
Jon Stonehouse
Algemeen directeur
US$4.8m
Totale compensatie
| Percentage CEO-salaris | 13.9% |
| Dienstverband CEO | 17.8yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 4.6yrs |
| Gemiddelde ambtstermijn bestuur | 5.2yrs |
Recente managementupdates
Recent updates
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$5m | US$666k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$7m | US$640k | -US$247m |
| Sep 30 2022 | n/a | n/a | -US$193m |
| Jun 30 2022 | n/a | n/a | -US$210m |
| Mar 31 2022 | n/a | n/a | -US$194m |
| Dec 31 2021 | US$7m | US$583k | -US$184m |
| Sep 30 2021 | n/a | n/a | -US$227m |
| Jun 30 2021 | n/a | n/a | -US$214m |
| Mar 31 2021 | n/a | n/a | -US$209m |
| Dec 31 2020 | US$6m | US$567k | -US$183m |
| Sep 30 2020 | n/a | n/a | -US$125m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$115m |
| Dec 31 2019 | US$2m | US$550k | -US$109m |
| Sep 30 2019 | n/a | n/a | -US$134m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$107m |
| Dec 31 2018 | US$4m | US$550k | -US$101m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$79m |
| Mar 31 2018 | n/a | n/a | -US$77m |
| Dec 31 2017 | US$4m | US$533k | -US$66m |
Compensatie versus markt: De totale vergoeding ($USD 4.78M ) Jon } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Jon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jon Stonehouse (63 yo)
17.8yrs
Tenure
US$4,777,778
Compensatie
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Executive Director | 17.8yrs | US$4.78m | 0.43% $ 6.6m | |
| Senior VP | 4.5yrs | US$1.79m | 0.082% $ 1.3m | |
| Senior VP | 18.1yrs | US$1.93m | 0.089% $ 1.4m | |
| Chief Research & Development Officer | 3.6yrs | US$2.39m | 0.055% $ 841.4k | |
| Senior VP & Chief Commercial Officer | 4.8yrs | US$1.74m | 0.10% $ 1.5m | |
| Chief Communications Officer | no data | geen gegevens | geen gegevens | |
| Chief People Officer | no data | geen gegevens | geen gegevens | |
| Chief Development Officer | 16.3yrs | US$2.66m | 0% $ 0 | |
| Chief Discovery Officer | 11yrs | US$2.57m | 0% $ 0 | |
| Chief Data & Insights Officer | 2.9yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer | 2.1yrs | geen gegevens | geen gegevens | |
| Chief Business Development Officer | 1.8yrs | geen gegevens | geen gegevens |
4.6yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Executive Director | 17.8yrs | US$4.78m | 0.43% $ 6.6m | |
| Independent Director | 3.3yrs | US$434.82k | 0.033% $ 508.4k | |
| Independent Director | 5.8yrs | US$446.90k | 0.024% $ 364.3k | |
| Independent Director | 4.7yrs | US$434.54k | 0.014% $ 209.2k | |
| Independent Director | 13yrs | US$432.74k | 0.0062% $ 95.5k | |
| Independent Director | 5.8yrs | US$433.57k | 0.022% $ 341.6k | |
| Independent Chair | 12.8yrs | US$470.30k | 0.034% $ 519.9k | |
| Independent Director | 3.1yrs | US$424.40k | 0.017% $ 258.2k | |
| Independent Director | 2.7yrs | US$423.15k | 0.010% $ 155.2k | |
| Independent Director | 3.1yrs | US$422.32k | 0.010% $ 156.0k |
5.2yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).